Ascentage Pharma Group International (AAPG) Competitors $41.40 -1.34 (-3.14%) As of 02:49 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock AAPG vs. GMAB, VTRS, RDY, ASND, QGEN, MRNA, BBIO, ELAN, VRNA, and BPMCShould you be buying Ascentage Pharma Group International stock or one of its competitors? The main competitors of Ascentage Pharma Group International include Genmab A/S (GMAB), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Qiagen (QGEN), Moderna (MRNA), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Ascentage Pharma Group International vs. Its Competitors Genmab A/S Viatris Dr. Reddy's Laboratories Ascendis Pharma A/S Qiagen Moderna BridgeBio Pharma Elanco Animal Health Verona Pharma PLC American Depositary Share Blueprint Medicines Genmab A/S (NASDAQ:GMAB) and Ascentage Pharma Group International (NASDAQ:AAPG) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability. Does the media prefer GMAB or AAPG? In the previous week, Genmab A/S and Genmab A/S both had 6 articles in the media. Ascentage Pharma Group International's average media sentiment score of 0.59 beat Genmab A/S's score of 0.58 indicating that Ascentage Pharma Group International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Ascentage Pharma Group International 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate GMAB or AAPG? Genmab A/S currently has a consensus price target of $37.60, suggesting a potential upside of 51.74%. Given Genmab A/S's higher probable upside, equities analysts clearly believe Genmab A/S is more favorable than Ascentage Pharma Group International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genmab A/S 1 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.64Ascentage Pharma Group International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in GMAB or AAPG? 7.1% of Genmab A/S shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is GMAB or AAPG more profitable? Genmab A/S has a net margin of 37.53% compared to Ascentage Pharma Group International's net margin of 0.00%. Genmab A/S's return on equity of 21.03% beat Ascentage Pharma Group International's return on equity.Company Net Margins Return on Equity Return on Assets Genmab A/S37.53% 21.03% 16.98% Ascentage Pharma Group International N/A N/A N/A Which has stronger earnings and valuation, GMAB or AAPG? Genmab A/S has higher revenue and earnings than Ascentage Pharma Group International. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenmab A/S$3.12B5.09$1.14B$1.9912.45Ascentage Pharma Group International$134.35M28.65-$55.54MN/AN/A SummaryGenmab A/S beats Ascentage Pharma Group International on 10 of the 13 factors compared between the two stocks. Get Ascentage Pharma Group International News Delivered to You Automatically Sign up to receive the latest news and ratings for AAPG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AAPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AAPG vs. The Competition Export to ExcelMetricAscentage Pharma Group InternationalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.97B$3.10B$5.76B$9.78BDividend YieldN/A2.26%3.95%4.03%P/E RatioN/A21.0830.8026.37Price / Sales28.65396.73467.21121.85Price / CashN/A44.4437.7659.36Price / Book40.998.0610.106.62Net Income-$55.54M-$54.08M$3.26B$265.42M7 Day Performance-12.29%3.95%3.91%3.58%1 Month Performance9.52%3.02%3.74%0.46%1 Year PerformanceN/A6.84%37.68%19.41% Ascentage Pharma Group International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AAPGAscentage Pharma Group InternationalN/A$41.40-3.1%N/AN/A$3.97B$134.35M0.00600Gap DownGMABGenmab A/S3.6884 of 5 stars$23.31+1.4%$37.60+61.3%-10.3%$14.74B$3.12B11.712,682News CoverageVTRSViatris1.9408 of 5 stars$10.61-0.7%$10.40-2.0%-11.4%$12.46B$14.74B-3.6632,000RDYDr. Reddy's Laboratories3.0648 of 5 stars$14.22+0.8%$16.95+19.2%-13.7%$11.78B$3.81B21.5527,811News CoverageASNDAscendis Pharma A/S3.4185 of 5 stars$198.32+3.3%$242.93+22.5%+42.0%$11.74B$490.75M-38.431,017Positive NewsQGENQiagen4.011 of 5 stars$49.36+0.8%$49.69+0.7%+11.3%$10.97B$2.04B29.165,765News CoverageMRNAModerna4.4998 of 5 stars$28.02+5.0%$43.59+55.6%-69.7%$10.38B$3.24B-3.725,800BBIOBridgeBio Pharma4.3042 of 5 stars$51.32+0.3%$61.35+19.5%+88.7%$9.78B$221.90M-12.55400ELANElanco Animal Health2.8457 of 5 stars$17.97-0.2%$17.33-3.5%+23.6%$8.92B$4.48B20.909,000Gap UpVRNAVerona Pharma PLC American Depositary Share2.4777 of 5 stars$105.27flat$109.00+3.5%+295.9%$8.61B$221.67M-106.3330Positive NewsBPMCBlueprint Medicines0.4116 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640News Coverage Related Companies and Tools Related Companies GMAB Alternatives VTRS Alternatives RDY Alternatives ASND Alternatives QGEN Alternatives MRNA Alternatives BBIO Alternatives ELAN Alternatives VRNA Alternatives BPMC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AAPG) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascentage Pharma Group International - Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascentage Pharma Group International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access